Cargando…
Preliminary Bioequivalence of an Oral Pimobendan Solution Formulation with Reference Solution Formulation in Beagle Dogs
Oral capsule and tablet formulations of pimobendan are widely used but may present difficulties for accurately dosing small patients. This study aimed to compare the pharmacokinetic (PK) characteristics, bioequivalence, and cardiovascular effects of a custom-made oral pimobendan solution (PS) formul...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955067/ https://www.ncbi.nlm.nih.gov/pubmed/35324869 http://dx.doi.org/10.3390/vetsci9030141 |
_version_ | 1784676248237113344 |
---|---|
author | Saengklub, Nakkawee Boonyarattanasoonthorn, Tussapon Kijtawornrat, Anusak Chantasart, Doungdaw |
author_facet | Saengklub, Nakkawee Boonyarattanasoonthorn, Tussapon Kijtawornrat, Anusak Chantasart, Doungdaw |
author_sort | Saengklub, Nakkawee |
collection | PubMed |
description | Oral capsule and tablet formulations of pimobendan are widely used but may present difficulties for accurately dosing small patients. This study aimed to compare the pharmacokinetic (PK) characteristics, bioequivalence, and cardiovascular effects of a custom-made oral pimobendan solution (PS) formulation compared to a reference solution (RS) formulation in conscious, healthy dogs. A randomized crossover design was performed on dogs that received RS and PS formulations at a dose of 0.3 mg/kg. Blood samples were collected at 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, and 24 h after oral administration for PK analysis; bioequivalence was also calculated. Echocardiography was also performed to assess the cardiovascular effects. The results revealed that the plasma concentrations of pimobendan and o-desmethyl-pimobendan (active metabolite) in the case of both formulations were comparable. The relative ratios of geometric mean concentrations for all significant parameters of PK were within a range of 80–125%, indicating bioequivalence. In addition, both formulations increased cardiac contraction significantly when compared with the baseline, and no differences in cardiac contractility were detected between the formulations. The PS formulation can be used as alternative to the RS formulation for the management of congestive heart disease because of the bioequivalence between the two formulations. |
format | Online Article Text |
id | pubmed-8955067 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89550672022-03-26 Preliminary Bioequivalence of an Oral Pimobendan Solution Formulation with Reference Solution Formulation in Beagle Dogs Saengklub, Nakkawee Boonyarattanasoonthorn, Tussapon Kijtawornrat, Anusak Chantasart, Doungdaw Vet Sci Article Oral capsule and tablet formulations of pimobendan are widely used but may present difficulties for accurately dosing small patients. This study aimed to compare the pharmacokinetic (PK) characteristics, bioequivalence, and cardiovascular effects of a custom-made oral pimobendan solution (PS) formulation compared to a reference solution (RS) formulation in conscious, healthy dogs. A randomized crossover design was performed on dogs that received RS and PS formulations at a dose of 0.3 mg/kg. Blood samples were collected at 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, and 24 h after oral administration for PK analysis; bioequivalence was also calculated. Echocardiography was also performed to assess the cardiovascular effects. The results revealed that the plasma concentrations of pimobendan and o-desmethyl-pimobendan (active metabolite) in the case of both formulations were comparable. The relative ratios of geometric mean concentrations for all significant parameters of PK were within a range of 80–125%, indicating bioequivalence. In addition, both formulations increased cardiac contraction significantly when compared with the baseline, and no differences in cardiac contractility were detected between the formulations. The PS formulation can be used as alternative to the RS formulation for the management of congestive heart disease because of the bioequivalence between the two formulations. MDPI 2022-03-17 /pmc/articles/PMC8955067/ /pubmed/35324869 http://dx.doi.org/10.3390/vetsci9030141 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Saengklub, Nakkawee Boonyarattanasoonthorn, Tussapon Kijtawornrat, Anusak Chantasart, Doungdaw Preliminary Bioequivalence of an Oral Pimobendan Solution Formulation with Reference Solution Formulation in Beagle Dogs |
title | Preliminary Bioequivalence of an Oral Pimobendan Solution Formulation with Reference Solution Formulation in Beagle Dogs |
title_full | Preliminary Bioequivalence of an Oral Pimobendan Solution Formulation with Reference Solution Formulation in Beagle Dogs |
title_fullStr | Preliminary Bioequivalence of an Oral Pimobendan Solution Formulation with Reference Solution Formulation in Beagle Dogs |
title_full_unstemmed | Preliminary Bioequivalence of an Oral Pimobendan Solution Formulation with Reference Solution Formulation in Beagle Dogs |
title_short | Preliminary Bioequivalence of an Oral Pimobendan Solution Formulation with Reference Solution Formulation in Beagle Dogs |
title_sort | preliminary bioequivalence of an oral pimobendan solution formulation with reference solution formulation in beagle dogs |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955067/ https://www.ncbi.nlm.nih.gov/pubmed/35324869 http://dx.doi.org/10.3390/vetsci9030141 |
work_keys_str_mv | AT saengklubnakkawee preliminarybioequivalenceofanoralpimobendansolutionformulationwithreferencesolutionformulationinbeagledogs AT boonyarattanasoonthorntussapon preliminarybioequivalenceofanoralpimobendansolutionformulationwithreferencesolutionformulationinbeagledogs AT kijtawornratanusak preliminarybioequivalenceofanoralpimobendansolutionformulationwithreferencesolutionformulationinbeagledogs AT chantasartdoungdaw preliminarybioequivalenceofanoralpimobendansolutionformulationwithreferencesolutionformulationinbeagledogs |